OMER
OMER clinical trials: OMEROS CORP
Every trial on ClinicalTrials.gov where OMEROS CORP is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 29
- Trials linked
- 25
- As lead sponsor
- 4
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
OMER on the catalyst calendar · OMER registry changes
- Primary completion Apr 14, 2026ActualPhase 2NCT06209736Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNOmeros Corporation · C3 GlomerulopathyTerminatedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06298955Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaOmeros Corporation · Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 3, 2025ActualPhase 1NCT05889299Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal HemoglobinuriaOmeros Corporation · Paroxysmal Nocturnal HemoglobinuriaCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2020ActualPhase 2NCT02682407Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721Omeros Corporation · IgANTerminatedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04247906Single Patient Expanded Access Treatment Plan For The Investigational Product NarsoplimabOmeros Corporation · Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)Approved for marketingOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2024ActualPhase 3NCT03608033Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyOmeros Corporation · IgA NephropathyTerminatedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2021ActualPhase 3NCT03205995Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeOmeros Corporation · Thrombotic MicroangiopathiesTerminatedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 10, 2024ActualPhase 2NCT05972967Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabOmeros Corporation · Paroxysmal Nocturnal HemoglobinuriaCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 2NCT05855083Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMAOmeros Corporation · Thrombotic MicroangiopathiesRecruitingOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2020ActualPhase 2NCT02222545Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesOmeros Corporation · Thrombotic MicroangiopathiesCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 12, 2016ActualPhase 3NCT02132312A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens ReplacementOmeros Corporation · Unilateral Cataract ExtractionCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2012ActualPhase 3NCT01406561Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic MeniscectomyOmeros Corporation · Meniscal TearCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2014ActualPhase 2NCT02074410Safety and Efficacy of OMS643762 in Subjects With Huntington's DiseaseOmeros Corporation · Huntington's DiseaseTerminatedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualPhase 2NCT01952132Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia SubjectsOmeros Corporation · SchizophreniaCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 3NCT02093689Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement SurgeryOmeros Corporation · Intraocular Lens ReplacementTerminatedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2012ActualPhase 3NCT01579565Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationOmeros Corporation · Intraocular Lens ReplacementCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2011ActualPhase 2NCT01193127Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)Omeros Corporation · CataractCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2012ActualPhase 3NCT01454063Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationOmeros Corporation · Intraocular Lens ReplacementCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2009ActualPhase 1/Phase 2NCT00721695Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.Omeros Corporation · Cataract ExtractionCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2010ActualPhase 1/Phase 2NCT00857090Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract StonesOmeros Corporation · Urinary CalculiCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2010ActualPhase 3NCT00226772Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) ReconstructionOmeros Corporation · Knee InjuriesCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2010ActualPhase 3NCT00226759Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) ReconstructionOmeros Corporation · Knee InjuriesCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2009ActualPhase 2/Phase 3NCT00624845Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing...Omeros Corporation · Postoperative PainCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2010ActualPhase 3NCT00245271Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) ReconstructionOmeros Corporation · Anterior Cruciate Ligament ReconstructionCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1NCT00599664Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located StonesOmeros Corporation · Urinary CalculiCompletedOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner